Hyperpolarized 13C Pyruvate as a Biomarker in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
This is a single center prospective imaging study investigating the utility of hyperpolarized
13C-pyruvate/metabolic MR imaging. The current protocol will serve as a companion imaging
biomarker study paired with standard of care (SOC) therapeutics, as well as investigational
therapies that participants may be scheduled to receive outside of this protocol.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Robert Bok, MD, PhD
Collaborators:
National Cancer Institute (NCI) National Institute for Biomedical Imaging and Bioengineering (NIBIB) Sigma-Aldrich